A Pharmacokinetic/Pharmacodynamic Study of the Glucocorticoid Receptor Antagonist Mifepristone Combined with Enzalutamide in Castrate-Resistant Prostate Cancer

Abstract

This is a Clinical Exploration Award funding a clinical trial for patients with metastatic, castration resistant prostate cancer (CRPC). For patients with metastatic CRPC, there are few established therapeutic options and the prognosis remains dire. The overarching goal of this award is to build on concept that under the selective pressure of androgen receptor (AR) targeted therapies, prostate cancer adapts. One way it adapts is by upregulating another hormone receptor, the glucocorticoid receptor (GR), which may compensate for diminished AR activity. The clinical trial within this award is a phase I/II clinical trial of the GR antagonist mifepristone in combination with the FDA-approved AR antagonist enzalutamide. Within the phase I portion, the study will examine the pharmacokinetics and safety of the two drugs in combination. The phase II portion is a multi-site

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Feb 01, 2020
Accession Number
AD1105335

Entities

People

  • Russell Szmulewitz

Organizations

  • University of Chicago

Tags

Communities of Interest

  • Biomedical

DTIC Thesaurus Topics

  • Abstracts
  • Alkynes
  • Androgen Receptors
  • Androgens
  • Biomedical Research
  • Castration
  • Clinical Trials
  • Data Analysis
  • Department Of Defense
  • Diseases And Disorders
  • Intellectual Property
  • Medical Personnel
  • Neoplasms
  • Patent Applications
  • Professional Development
  • Prostate
  • Prostate Cancer

Fields of Study

  • Biology
  • Medicine

Readers

  • Oncology
  • Prostate Cancer Biology.